findmyKOL
Clinical trialNCT00271063UnknownPhase 1/PHASE2Interventional

Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

SponsorCallisto PharmaceuticalsEnrollment34Acute Lymphocytic Leukemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Roswell Park Cancer Institute

    Buffalo, New York, United States

    Meir Wetzler, MD
    Recruiting
  • Montefiore Medical Center

    The Bronx, New York, United States

    Samir Parekh, MD
    Recruiting
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Hagop Kantarjian, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Liposomal Annamycin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2005
Primary completion
—
Completion
30 Apr 2008
Last update posted
21 Dec 2007
Registered enrollment
34
Registry id
NCT00271063
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.